Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

Analysts at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Wednesday. The brokerage set a “hold” rating on the medical research company’s stock.

CTSO has been the topic of several other reports. B. Riley reiterated a “buy” rating and issued a $3.00 price objective on shares of Cytosorbents in a research note on Wednesday, May 15th. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a research note on Tuesday, May 7th.

Cytosorbents Stock Performance

Shares of CTSO stock opened at $0.75 on Wednesday. The firm has a market cap of $40.90 million, a P/E ratio of -1.28 and a beta of 0.61. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.21 and a current ratio of 1.49. Cytosorbents has a one year low of $0.75 and a one year high of $4.29. The firm’s 50 day moving average price is $0.87 and its 200-day moving average price is $1.02.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). The firm had revenue of $9.79 million for the quarter, compared to the consensus estimate of $9.78 million. Cytosorbents had a negative return on equity of 129.89% and a negative net margin of 75.07%. During the same quarter in the previous year, the business earned ($0.17) EPS. As a group, equities research analysts predict that Cytosorbents will post -0.36 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CTSO. Avenir Corp grew its holdings in shares of Cytosorbents by 4.0% in the 1st quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after acquiring an additional 121,294 shares during the period. CM Management LLC grew its stake in Cytosorbents by 98.8% in the 1st quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock valued at $784,000 after acquiring an additional 410,000 shares during the last quarter. Key Client Fiduciary Advisors LLC raised its position in Cytosorbents by 188.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock worth $33,000 after acquiring an additional 22,557 shares during the last quarter. Neuberger Berman Group LLC lifted its holdings in shares of Cytosorbents by 19.9% in the fourth quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock valued at $1,997,000 after purchasing an additional 299,103 shares in the last quarter. Finally, Skylands Capital LLC grew its position in shares of Cytosorbents by 10.5% in the fourth quarter. Skylands Capital LLC now owns 3,254,213 shares of the medical research company’s stock valued at $3,612,000 after purchasing an additional 309,543 shares during the last quarter. 32.87% of the stock is currently owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.